Bagsværd, Denmark, 29 September 2017 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Fiasp® (fast-acting insulin aspart), a new fast-acting mealtime insulin, for the treatment of adults with diabetes. The FDA's decision comes after Fiasp® in clinical trials demonstrated benefits for people in need of improved overall glucose control.
Fiasp® is an innovative formulation of insulin aspart (NovoLog®) developed with the aim of obtaining pharmacokinetic and pharmacodynamic properties that more closely match the natural physiological insulin mealtime response of a person without diabetes.
In clinical trials Fiasp® has demonstrated clinically relevant improvement in long-term glucose level (HbA1c). These results were achieved with a comparable overall rate of severe or blood-sugar confirmed hypoglycaemia, between Fiasp® and insulin aspart.
"We are very pleased that Fiasp® will now also be available to people with diabetes in the US," said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. "The fast action profile of Fiasp® allows people with diabetes convenient timing in terms of when to take their insulin in connection with meals to achieve the optimal blood sugar control."
About Fiasp®
Fiasp® is insulin aspart in an innovative formulation, in which two excipients have been added: Vitamin B3 (niacinamide) to increase the speed of absorption and a naturally occurring amino acid (L-Arginine) for stability. The review of Fiasp® was based on the 'onset' programme, a phase 3 clinical programme comprising four trials encompassing more than 2,100 people with type 1 and type 2 diabetes.
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 41,400 people in 77 countries and markets its products in more than 165 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com (http://www.novonordisk.com),Facebook (http://www.facebook.com/novonordisk), Twitter (http://www.twitter.com/novonordisk), LinkedIn (http://www.linkedin.com/company/novo-nordisk), YouTube (http://www.Youtube.com/novonordisk)
Further information
| Media: | ||
| Katrine Sperling | +45 4442 6718 | krsp@novonordisk.com (mailto:krsp@novonordisk.com) |
| Ken Inchausti (US) | +1 609 786 8316 | kiau@novonordisk.com (mailto:mailtokiau@novonordisk.com) |
| Investors: | ||
| Peter Hugreffe Ankersen | +45 3075 9085 | phak@novonordisk.com (mailto:phak@novonordisk.com) |
| Hanna Ögren | +45 3079 8519 | haoe@novonordisk.com (mailto:haoe@novonordisk.com) |
| Anders Mikkelsen | +45 3079 4461 | armk@novonordisk.com (mailto:armk@novonordisk.com) |
| Christina Kjær | +45 3079 3009 | cnje@novonordisk.com (mailto:cnje@novonordisk.com) |
| Kasper Veje (US) | +1 609 235 8567 | kpvj@novonordisk.com (mailto:kpvj@novonordisk.com) |
Company Announcement No 74 / 2017
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire
